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Abstract  
Ethnopharmacological relevance: Coptidis Rhizoma (Huanglian) and its major component, 
berberine, have drawn extensive attention towards their antineoplastic effects in the recent 
years. The antineoplastic effects are related to the Chinese Medicine (CM) properties of 
Huangliang in treating diseases by removing damp-heat and purging fire and counteracting 
toxicity.       
Aim of the review: To trace the long history of the traditional use of Huanglian from folk 
medicines, especially from Chinese medicine, to recent pharmacological studies of Huanglian 
and berberine, with an emphasis on their antineoplastic effects and the promise as novel 
antineoplastic agents.  
Methods: A total of 7 databases were extensively searched for literature research. The terms 
and keywords for searching included Huanglian, berberine, Coptis, Coptidis Rhizoma, 
anticancer, antiinvasion, antimatastasis and mechanism. The papers including ours with 
studies on anticancer and mechanism, pharmacology and toxicology of Huanglian and/or 
berberine were focused.  
Results: In view of traditional use, the anticancer effects of Huanglian can be ascribed to its 
CM trait by removing damp-heat, fire and toxicity. From modern biomedical studies, 
anticancer effects have been demonstrated in both Huanglian and berberine. The underlying 
molecular mechanisms involve cell cycle arrest, apoptosis induction and antiinflammation. 
Berberine is an essential anticancer compound in Huanglian. In some studies, the use of 
Huanglian was shown to be more effective and beneficial than the use of berberine alone. The 
presence of other protoberberine-type alkaloids in Huanglian might give synergistic effects 
for the anticancer effects. Berberine also demonstrates effects of antiangiogenesis, 
antiinvasion and antimetastasis in some cancer cell lines, however, more investigations are 
required to unravel the underlying mechanisms involved.  
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Conclusions: The modern evidences of treating cancer with Huanglian and berberine have a 
strong linkage with traditional concept and rules of using Huanglian in CM practice. As 
anticancer candidates with low toxicity, berberine and its altered structure, as well as 
Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects 
and the mechanisms by using technologies of genomics, proteomics and other advanced 
approaches. On the other hand, relatively few in vivo studies have been conducted on 
anticancer effects of Huanglian and berberine. The clinical application of berberine or 
Huanglian as novel cancer therapeutic agents requires in vivo validations and further 
investigations of their anticancer mechanisms. 
 
Keywords: Traditional Chinese medicine; Coptidis Rhizoma; Huanglian; Berberine; 
Antineoplastic agent; mechanisms of anticancer action  
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Abbreviations:  AP-1: activator protein 1; ATF3: activating transcription factor 3; Bcl-2: B 
cell lymphoma/leukemia-2; BCD: berberine chloride dihydrate; BCL: berberine hydrochloride; 
CDK: cyclin-dependent kinase; COX-2: cyclooxygenase-2; FasL: factor associated suicide 
ligand; GADD153: growth arrest and DNA damage inducible gene 153; GAP: good 
agricultural practice; HIF: hypoxia inducible factor; Huanglian extract: the water extract of 
Huanglian; IC50: fifty percent inhibitory concentration; ID50: fifty percent inhibitory dose; 
IFN: interferon; IκB: inhibitor of NF-κB; IKK: IκB kinase; IL: interleukin; JNK, c-Jun N-
terminal kinase; LOAEL: lowest observed adverse effect level; MAPK: mitogen-activated 
protein kinase; MDR: multidrug resistance; MLD: minimal lethal dose; MMP: mitochondrial 
membrane potential; MMPs: matrix metalloproteinases; NAG-1: nonsteroidal anti-
inflammatory drug activated gene; NCI: National Cancer Institute; NDEA: N-
nitrosodiethylamine; NF-κB: nuclear factor-κB; NOAEL: no observed adverse effect level; 
PARP: poly ADP-ribose polymerase; ROS: reactive oxygen species; CM: traditional Chinese 
medicine;  TNF: tumour necrosis factor; Urokinase-type plasminogen activator: u-PA.   
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
7 
1. Introduction 
 
Coptidis Rhizoma (Huanglian in Chinese) has been used for more than two thousand years 
by CM physicians for treatment of damp-heat syndromes (Chinese Herbals Editor Board, 
1999). Berberine (Fig. 1) is an isoquinoline alkaloid commonly used in both China and other 
countries as a botanic drug which is also a major active compound in Huanglian. It is widely 
present in the plant kingdom: Berberidaceae Ranunculaceae and Papaveraceae (Felter and 
Lloyd, 1898; Galle et al., 1994; Lenka et al., 2007). In this review, we focused on Huanglian 
of Ranunculaceae, because traditional use and ethnopharmacological relevance of Huanglian 
is link to biomedical investigations of Huanglian and berberine. As specified in the Chinese 
Pharmacopoeia (The State Pharmacopoeia Commission of the P.R. China, 2005), Huanglian 
may contain three Coptis species: Coptis chinensis Franch. (Weilian in Chinese), Coptis 
deltoidea C. Y. Cheng et Hsiao. (Yalian in Chinese) and Coptis teetoides C. Y. Cheng (or 
Coptis teeta Wall., Yunlian in Chinese) (Fam. Ranunculaceae).  There are a few other native 
Coptis species distributed in other areas of the world which are also used as Huanglian, e.g. 
Coptis japonica Makino. in Japan (Society of Japanese Pharmacopoeia, 2001) and Coptis 
trifolia Salisb. (or Goldthread) which were used as domestic medicines in North America 
(Lloyd and Lloyd, 1887). In China, Weilian has been extensively cultivated in eastern Sichuan 
and western Hubei provinces under good agriculture practice (GAP) for Chinese Crude Drugs 
(Xu et al., 2004) (Fig. 2). It is worthwhile to note that the wild Yunlian has been remarked as 
vulnerable with the conservation status ranking No. 2 in China. Nevertheless, its status as an 
herbal drug would not be greatly influenced due to a similar extensive cultivation to Weilian 
in the southwestern part of China.  Berberine is an alkaloid component in Huanglian. The 
recent studies confirmed that Huanglian is a good producer of berberine. Berberine constitutes 
the most abundant alkaloid in the dried herb (5.20%-7.69%, w/w) (Iizuka et al., 2000a; Xu et 
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al., 2004). High production of berberine can also be achieved via modifications of metabolic 
pathways in plants by genetic engineering (Sato et al., 2001). 
The main pharmacodynamic properties of berberine and Huanglian have long been 
recognized on the treatment of intestinal infections including acute gastroenteritis, cholera and 
bacillary dysentery which can be linked to their antibacterial, antiviral and anti-inflammatory 
effects (Amin et al., 1969; Subhuti, 2005; Kyoko et al., 2007). The purification of berberine 
from Huanglian has greatly facilitated investigation studies into the therapeutic applications 
of Huanglian. 
The development of Huanglian and berberine in clinical applications can be broadly 
divided into several stages:  
(a)  Early clinical use of Huanglian in CM began at about 2000 years ago in the treatment of 
diarrhea, eye inflammation and women‟s abdomen ailments caused by damp-heat, which 
is still a common use of Huanglian today in CM (Xu et al., 2004; Chen and Gao, 1997a 
and 1997b).  
(b) Early medical uses and development of berberine-containing botanic drugs in North 
American folk medicine in the treatment of sub-acute and chronic inflammations 
including gastric disorders, respiratory affections and cancer during the 1800s; but 
gradually lost their application status in western medicine (Lloyd and Lloyd, 1887; Felter 
and Lloyd, 1898). 
(c) The pre-clinical and clinical studies and development of berberine as a natural antibiotic to 
treat various bacteria-associated diarrheas in the late 1900s (Dutta and Panse, 1962; 
Subbaiah and Amin, 1967; Khin et al., 1985; Rabbani et al., 1987). 
It is worth highlighting that the antineoplastic activities of berberine have been reported 
intermittently (Hano, 1959). The initial positive results from these studies together with the 
information from CM led to reconsideration of the use of berberine and Huanglian in the 
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treatment of cancer diseases. After 1990s, there were more studies on the antineoplastic 
effects of berberine and Huanglian in diverse cancer cell types, and the underlying 
mechanisms of the antineoplastic action were also investigated especially on those of 
berberine. Meanwhile, many other pharmacological benefits have also been reported 
including lowering of blood cholesterol (Kong et al., 2004), anti-inflammatory effects (Kuo et 
al., 2004), therapies of experimental colitis (Zhou and Mineshita, 2000) and treatment of 
diabetes (Zhou et al., 2007) for berberine, hepatoprotective (Ye et al., 2009) and anticachectic 
effects (Iizuka et al., 2000b) for Huanglian.  
In this review, the history of the early development of Huanglian and berberine as botanic 
drug was traced at first and recent publications on their effects on various cancer cell types 
and the underlying antineoplastic mechanisms, genomics, proteomics and computer-aided 
molecular design as well as in vivo studies, general pharmacology and toxicology were then 
focused in English and Chinese databases. No restrictions regarding the language of 
publication were imposed, but most relevant studies were published in English and Chinese 
bibliographies, the electronic literature searches were conducted in the following databases (6 
English databases and 1 Chinese database): MEDLINE (1966 to date, via Pubmed), EMBASE 
(1974 to date), CINAHL (Cumulative Index to Nursing and Allied Health Literature, 1982 to 
date), AMED (Allied and Complementary Medicine Database, 1985 to date), The Cochrane 
Central Register of Controlled Trials (CENTRAL),EBM Reviews Full Text - CDSR, ACP 
Journal Club, and DARE (1991 to date) and China Journals Full-text Database (1915 to date, 
via CNKI). The following search key words or terms were used: Huanglian, berberine, Coptis, 
Coptidis Rhizoma, anticancer, antineoplastic mechanisms, genomics, proteomics and 
computer-aided molecular design as well as in vivo studies, general pharmacology and 
toxicology. Further manual searches were conducted in our own files as well as in the 
reference lists of all located articles. After systematic review, we did not find any review 
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paper for the anticancer efficacy and safety of Huanglian and berberine until this paper was 
completed. 
All articles were read in full by all authors and data relating to anticancer, genomics, 
proteomics and computer-aided molecular design as well as in vivo studies, general 
pharmacology and toxicology of Huanglian and/or berberine and results were extracted by 
authors. The authors agreed to a consensus on the assessed data and cases of discrepancy 
would be settled by discussion. Articles which are included in the study had to meet all of the 
following criteria: (a) experimental studies on anticancer effects of Huanglian and/or 
berberine; (b) explore underlying mechanisms for anticancer, antiinvasive and antimetastatic  
effects of Huanglian and/or berberine; (c) new approach such as genomics, proteomics and 
computer-aided molecular design to studies on anticancer effects of Huanglian and/or 
berberine; (d) animal studies and clinical trails for anticancer effects of Huanglian and/or 
berberine; (e) general pharmacological and toxicological effects of Huanglian and/or 
berberine; (f) traditional use and ethnopharmacological relevance to anticancer effects of 
Huanglian and/or berberine; (g) articles in English were preferred, but some information 
which can be only found in Chinese (partially information in d, e and f) were also included. 
Articles out of the above criteria were excluded. As a result, over 100 peer-reviewed 
international papers in English as well as 21 peer-reviewed papers or books in Chinese and 5 
web information have been cited (136 reference papers in total) This is a first review paper 
which provided a whole picture and related information on topic of antineoplastic effects of 
Huanglian and berberine. The potential values of berberine and Huanglian as novel 
antineoplastic agents for future clinical application are also discussed. The plant sources, 
biosynthesis, pharmacological actions and phytochemistry of berberine and cultivation of 
Huanglian can be referred to other review articles published (Li et al., 2008a; Lenka et al., 
2007; Yu et al., 2006; Xu et al., 2004). 
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2. The early history of Huanglian and berberine development as botanic drugs   
 
2.1. The early years of Huanglian development 
 
The earliest record of Huanglian can be dated back to Shen Nong’s Herbal Classic 
compiled in the Han Dynasty of China (about A.D. 200), in which Huanglian was regarded as 
one of the top-grade drugs (tonic and non-toxic) (Xu et al., 2004; Wu et al., 1982). Since then, 
the use of Huanglian was frequently cited in many other official or un-official medical 
compilations e.g. Shang Han Lun (Treatise on Cold-induced Febrile Diseases) and Jin Kui 
Yao Lue (Synopsis of Prescriptions of the Golden Chamber, about A.D. 210, Han Dynasty), 
Wai Tai Mi Yao (Medical Secrets from the Royal Library, A.D. 752, Tang Dynasty), and Ben 
Cao Gang Mu (Compendium of Materia Medica, A.D. 1596, Ming Dynasty) (Chen and Gao, 
1997a and 1997b). Huanglian is an important component in many traditional Chinese 
compound formulae (Fufang in Chinese).  At least 1,760 Huanglian formulae have been 
recorded in Chinese Herbals until Song Dynasty (A.D. 1279), and about 108 of which are still 
in use today (Chen and Gao, 1997a). The well-known and useful ones, such as Xie Xin 
Decoction from Jin Kui Yao Lue and Huanglian Jiedu Decoction from Wai Tai Mi Yao, have 
received great attention in evidence-based studies (Feng, 2000; Ohta et al., 2004).  
Huanglian can remove damp-heat, fire and counteract toxicity, both of which are related to 
inflammatory or tumour pathogenesis in CM (Chinese Herbals Editor Board, 1999; Liao et al, 
2003). Its traditional use in the treatment of diseases such as stuffiness and fullness of 
abdomen, diarrhea, vomiting, high fever, fidgetiness and insomnia, eye inflammation, 
diabetes, carbuncles and sores as specified in Chinese Pharmacopoeia may be results of 
multiple pharmacological properties including anti-inflammatory and anticancer activities of 
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Huanglian. The CM physicians may not have recognized the pathological nature of some 
diseases as clearly as western medicine. For example, in CM, tumours were described as 
„lumps‟ or „carbuncles‟ in the body and were usually believed to be caused by heat-induced 
toxicity and stagnation of qi and blood. There were indeed some approaches to treat „tumours‟ 
in CM practices by clearing blood stagnation, lumps, to remove heat and to counteract toxicity 
(Liao et al, 2003).  
In other traditional medicines such as Ayurvedic medicine and early western medicine, in 
the year of 1800s, the use of berberine-containing botanic drugs was also dominant including 
the Indian Barberry (Berberis aristata DC., Berberidaceae), European Barberry (Berberis 
vulgaris L., Berberidaceae), American Hydrastis (Hydrastis canadensis L. or Goldenseal, 
Ranunculaceae) and Goldthread. The American Hydrastis was largely used both as a medicine 
and as a coloring material among certain aboriginal tribes of North America. In his first 
edition of „Collections for an Essay Toward a Materia Medica of the United States‟ (1798), B. 
S. Barton had referred to the Cherokee use of Hydrastis as a cure for cancer, which may 
represent the oldest recorded use of berberine-containing botanic drugs for cancer treatment. 
Some homoeopathic practitioners even suggested long and continued use of Hydrastis to 
retard scirrhus of the breast (Felter and Lloyd, 1898). However, evidence of pre-clinical or 
clinical studies for these herbs was scanty at that stage. The official use of these botanic drugs 
gradually diminished in the late 1800s.  
 
2.2. The early years of berberine development 
 
Berberine was firstly isolated and identified as a plant isoquinoline alkaloid (Lenka et al., 
2007) in the early nineteenth century (Felter and Lloyd, 1898). In the succeeding years from 
1910s to 1960s, the chemistry and synthesis of berberine was thoroughly studied (Johannes 
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and Rose, 1930; Huffman and Miller, 1960) and total synthesis of berberine was achieved in 
1969 (Kametani et al., 1969). In the early 1960s, berberine and its salts, such as berberine 
sulphate, had been demonstrated to be valuable to treat cholera, severe diarrhea and 
amoebiasis by Indian researchers (Dutta and Panse, 1962; Subbaiah and Amin, 1967). Clinical 
trials of berberine to treat bacterial diarrhea were reported in 1985 and 1987 (Khin et al., 1985; 
Rabbani et al., 1987). Berberine itself may not be an effective antibiotic; however, its anti-
microbial activity is potentiated by the MDR inhibitor, 5‟-methoxyhydnocarpin, which does 
not have antimicrobial activity on its own (Stermitz et al., 2000). This study showed that 
Huanglian extract may have higher therapeutic effects than berberine alone and may be the 
results of synergistic actions of other components present in Huanglian. In China, berberine 
was isolated and used as a botanic drug in the late 1950s (Subhuti, 2005). The initial clinical 
application was for treatment of intestinal infections.  
The early development of berberine into an anticancer agent was not as promising as its 
application as a natural antibiotic agent. However, later screening of the Native American 
anticancer Hoxsey formula, a mixture of botanic drugs containing Barberry (Berberis vulgaris 
L.), resulted in the identification of berberrubine as the antitumour principal (Patricia et al., 
2002; Hoshi et al., 1976). Interestingly, berberrubine is not present as the natural form in the 
botanic drug (Lenka et al., 2007).  It is most likely an in vivo metabolite of berberine that is 
active for cancer therapy (Zuo et al., 2006). 
 
2.3. The link between traditional use and modern research of berberine and Huanglian 
for cancer therapies 
 
Even though there are few indications of Huanglian in early history directly related to 
treatment of cancer, clues and implications can be derived from traditional uses of Huanglian 
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in the treatment of diseases with similar symptoms of tumours, as well as basic research 
especially on its main active principal, berberine. In modern concepts, cancer is characterized 
by a rapid and uncontrolled formation of abnormal cells, which may mass together to form a 
growth or tumour, proliferate throughout the body and initiate abnormal growth at other sites. 
Therefore, anticancer drugs involve pharmacological effects of cytotoxicity, antiproliferation, 
antiinflammation, cell cycle arrest, apoptosis induction, antiinvasion and antimetastasis etc..  
There is no concept of cancer in ancient CM, but some symptoms may relate to cancer. 
Symptoms such as diarrhea, vomiting, fever, and bleeding are not specific symptoms, cancer 
may also show similar symptoms. Huanglian, firstly recorded in Shen Nong’s Herbal Classic 
(the oldest herbal compilation in China) to treat diarrhea, inflammation of the eye, and 
women‟s abdomen ailments caused by damp-heat, also has long been used for the treatment 
of these diseases in CM practice (including its formulae). The syndromes with the trait of 
damp-heat or heat-toxicity can be easily linked to the modern concept of infection or 
inflammation. Therefore, the early pharmacological study of Huanglian and its formulae were 
found to be beneficial in anticontagious and antiinflammatory effects. In current studies, many 
cytokines released by cancer cells can be directly translated to be a similar target of anti-
inflammatory drugs (Lee et al., 2007a). While the precise mechanisms underlying antitumour 
effects remain to be investigated, there is increasing evidence showing that Huanglian and/or 
berberine may inhibit the inflammation-triggered tumorigenesis (Izuka et al., 2000; Kuo et al., 
2004; Lee et al., 2007b; Pandey et al., 2008). Inflammation and cancer have been viewed as 
vicious partners in crime and their relationship has become a hot topic for cancer research 
(Balkwill and Mantovani, 2001; Coussens and Werb, 2002; Mantovani and Balkwill, 2006; 
Lu et al., 2006). During inflammation, cytokine, growth factors and free radicals are produced, 
to activate transcription factors including NF- B and downstream cancer-related genes 
(Hussain and Harris, 2007). The link between anticancer and antiinflammation, can be 
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established after antiinflammation, anticachectic, antioxidant, antiproliferation and 
antiinvasion properties of berberine, Huanglian and/or its formulae have been discovered in 
vitro and in vivo (Fukuda et al., 1999a, 1999b; Izuka et al., 2000b; Anis et al., 2001; Wang et 
al., 2002; Jantova et al., 2003; Kuo et al., 2004; Peng et al., 2006; Lee et al., 2007b; Ye et al., 
2009, Tsang et al, 2009).  
In many modern Chinese herbal books about tumour treatment, Huanglian is chosen as one 
of the anticancer herbal drugs and is widely used in routine CM practice (Tse, 1977; Qian, 
1980; Xu et al, 1997; Chang, 1998; Bo, 2002, Feng et al, 2008). In view of CM, the anticancer 
effect of Huanglian can be ascribed to one of the CM traits by clearing damp-heat or 
removing heat and toxicity (Chinese Herbals Editor Board, 1999; Liao et al, 2003), while from 
biomedical studies, cytotoxic, antiproliferative, antiinflammatory, antiinvasive and 
antimetastatic effects should all contribute to anticancer effects of Huanglian and berberine 
(Izuka et al., 2000; Jantova et al., 2003; Kuo et al., 2004; Peng et al., 2006; Lee et al., 2007b, 
Tsang et al., 2009). In view of historical development, modern studies and clinical 
applications, anti-inflammatory effect was frequently mirrored in Huanglian application in 
many classic herbal books, for example, four formulae containing Huanglian (Coptidis 
Rhizoma) such as Gegen HuanqQin Huanglian decoction (Puerariae Radix, Scutellariae 
Radix, Coptidis Rhizoma, Glycyrrhizae Radix), Banxia Xiexin decoction (Pinelliae Rhizoma, 
Scutellariae Radix, Coptidis Rhizoma, Zingiberis Rhizoma, Giensen Radix, Ziziphi Jujubae 
Fructus, Glycyrrhizae Radix), Huanglian decoction (Coptidis Rhizoma, Pinelliae Rhizoma, 
Cinnamoni Ramulus, Zingiberis Rhizoma, Ginseng Radix, Ziziphi Jujubae Fructus, 
Glycyrrhizae Radix) from Shang Han Lun and Jin Kui Yao Lue, Huanglian Jiedu decoction 
(Coptidis Rhizoma, Scutellariae Radix, Phellodendri Cortex, Gardeniae Fructus) from Wai Tai 
Mi Yao and Zuo Jin Wan (Coptidis Rhizoma and Evodiae Fructus)  from Dan Xi Xin Fa (A.D. 
1481, Ming Dynasty) are usually used to treat stomach ache, vomiting, fever, bleeding and 
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diarrhea, which are strongly related to infections, inflammations and even cancers (Feng et al, 
2008).  
As a classic formula, Huanglian Jiedu decoction has been prescribed to treat gastroenteritis, 
ulcer, acute febrile illnesses and tumours nowadays, in which a pharmacological basis was 
studied (Sun et al., 2006). This decoction is the aqueous extract of a mixture of four herbs 
with Huanglian as a major component. All herbs have some similar nature to Huanglian for 
heat removal, suggesting an integrated anti-inflammatory effect, which may be more easily 
understood from a traditional view of CM.  Our clinical observations have shown that 
Huanglian-containing formulae were also effective for treating adenoma and carcinoma of the 
large intestine,  Hilar Cholangicarcinoma (Low and Feng, 2004; Feng et al, 2008). It could be 
hypothesized that Chinese medicines with a similar druggable nature to Huanglian, may also 
have effective antitumour effects in CM practice. This idea forms one basis for our future 
effort to establish links between CM and western counterparts. 
In reality regarding CM practice, practitioners rarely use a pure compound or single herbal 
drug to treat diseases, but use a combination of single herbs to mix together (so called Fufang, 
or composite formula). It is a common model for many Chinese medicines studies in recent 
years, the goal of research is to “dig out” major active single herb(s) in a composite formula 
for some diseases and further explore active compound(s) in the single herb(s). To the 
contrary, CM practitioners always integrate traditional use with results derived from modern 
research. For example, a CM practitioner may use Huanglian combined with other herbs or 
Huanglian Jiedu decoction to treat cancer, but not berberine. Berberine is one of the active 
compounds from Huanglian but they are not equal with each other. The effects and 
mechanisms of Huanglian should include those of berberine; however, berberine would not 
fully represent that of Huanglian. Thus, Huanglian and berberine in this review have been 
described separately in order to establish differentiation and their innate correlation.  
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Numerous experimental studies of Huanglian and berberine on antitumour, as well as in 
modern CM practice, have been carried out in recent years, the topic of antiinflammation and 
anticancer is also a most recent issue. Therefore, Huanglian and berberine are defined in the 
title as the novel antineoplastic agents. From views of traditional use and pharmacological 
studies, Huanglian and berberine inhibit inflammation-triggered tumorigenesis, whereby clues 
have been found from traditional use, but other anticancer effects such as cytotoxicity, 
antiproliferation, cell cycle arrest, apoptosis, antiinvasion and antimetastasis were discovered 
in the last ten years, which can be considered as new findings from scientific research. 
 
3. The pharmacological studies of berberine and Huanglian for cancer therapies  
 
3.1. Cancer cell lines used and antiproliferation properties of berberine 
 
Just as mentioned above, intensive studies on antineoplastic effects of berberine have 
occurred since the 1990s. Numerous cancer cell lines, either human or murine, have been used 
to examine the cytotoxic effects of berberine. Berberine could inhibit the growth of many 
cancer cell lines in vitro at a relatively low IC50. The cancer cell types, which were sensitive to 
berberine, are broad including both hematological and non-hematological cancer arising from 
leucocytes, liver, lung, stomach, colon, skin, oral, esophagus, brain, bone, breast and sexual 
organs (either hormone-dependent or independent). In some cases, the IC50 of berberine was 
lower than 4 µg/mL, which is below the safety limit established by National Cancer Institute 
(NCI) (Letašiová et al., 2006), indicating the potential of berberine as an antineoplastic drug 
on human cancer e.g. human cervical cancer, leukemia or colon cancer. Recently, we have 
confirmed the cytotoxicities of berberine on various cancer cell lines including HONE 1 
(nasopharyngeal carcinoma), HK1 (nasopharyngeal carcinoma), HeLa (cervical carcinoma) 
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18 
and HepG2 (hepatocellular carcinoma) cancer cell lines in a dose- and time-dependent manner, 
this confirms the broad spectrum of antineoplastic activity of berberine (unpublished data). 
 
3.2. Underlying mechanisms involved in the cytotoxicities of berberine  
 
Recent advances in the study of cell cycle checkpoint controls and DNA repair, have 
identified key small-molecule inhibitors of the cell cycle relevant to understanding the 
mechanisms of cancer chemotherapeutic agents (Leland and Michael, 1994; Crews and 
Shotwell, 2003). Berberine can induce DNA topoisomerase I poisoning and apoptotic cell 
death (Kettmann et al, 2004a). Many more recent findings, stapled into the antineoplastic 
story of berberine, are based on the knowledge of cell cycle regulation and the downstream 
effects or phenotypes related to cell-cycle inhibition, particularly the caspase(s)-dependent 
apoptosis and associated cell signaling pathways. The intrinsic apoptotic pathways are vital 
for many normal physiological processes and initiated by a series of apoptotic regulatory and 
effector proteins such as caspases.  Aberrant or dysregulated apoptotic response contributes to 
the development of cancer (Reed, 2002). There are two main pathways for cell death by 
triggering the activation of the caspase(s) cascade. One pathway induces apoptosis via 
interaction of the Fas/FasL system (the extrinsic cell death pathway). Fas is a member of  the 
tumour necrosis factor (TNF) death receptor family, which plays a key role in linking drug-
induced damage to apoptotic cell processes. Another one is the activation of the mitochondrial 
pathway (the intrinsic pathway). Studies on treatment of cancer by berberine indicated that 
apoptosis is involved in the many cancer cell lines examined. The underlying mechanisms for 
apoptosis induction by berberine, in more or less degree of diversity, are summarized below. 
More details can be referred to in Fig. 3.  
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(a) Cell cycle arrests at G0/G1, G1 and/or G2/M, and coordinated suppression of cyclin-
dependent kinases (e.g., CDK 2, 4, 6) and cyclins (e.g., cyclin B, D, E) (Eom et al., 2008; 
Mantena et al., 2006a and 2006b; Lin et al., 2006b; Lin et al., 2006c; Kang et al, 2005; 
Jantova et al., 2003). Our current studies on human nasopharyngeal carcinoma cells 
(HONE1 cells), suggest that berberine could induce apoptosis via G2 arrest which 
demonstrated by increased levels of cleaved-PARP, cleaved caspase 3 and cleaved 
caspase 9 (Tsang et al., 2009). In some cases, the induction of cell cycle arrest was relied 
on p53 status, for example, G1 arrest was induced in HCO and U2OS cells (p53 
functional), but G2/M arrest in Saos-2 cells (p53 deficient) (Liu et al., 2009a); in others, 
the cell cycle arrest in G0/G1 phase was much higher in p53 expressing SK-N-SH cells 
than those in p53-deficient SK-N-MC cells (Choi et al., 2008), and also the case in p53 
positive LNCaP prostate cells than those in p53 negative PC-3 cells (Choi et al., 2009). 
(b) The mitochondria/caspase-dependent and/or Fas/FasL signal pathways, evidenced by the 
altered ratio of anti-apoptotic (Bcl-2 proper, Bcl-XL) and pro-apoptotic (Bax, Bid) 
members of the Bcl-2 family proteins (Eom et al., 2008; Hsu et al., 2007; Mantena et al., 
2006a and 2006b; Lin et al., 2006a; Lin et al., 2006c), loss of mitochondria membrane 
potential and/or release of cytochrome c (Lin et al., 2007a; Jantova et al., 2007; Hwang et 
al., 2006; Lin et al., 2006a; Lin et al., 2006c; Mantena et al., 2006a and 2006b), induction 
of reactive oxygen species (ROS) and/or Ca
2+
 production (Meeran et al., 2008; Lin et al., 
2007a and 2007b; Jantova et al., 2007; Hsu et al., 2007; Lin et al, 2006a; Lin et al., 2006c), 
activation of Fas or FasL (Hsu et al., 2007; Hwang et al., 2006) as well as activation of a 
series of caspases, especially the downstream executioner, caspase-3.  
 (c) Many other cell signaling pathways have also been found to be associated with the 
anticancer effects of berberine. Hsu et al. (2007) have reported a new mechanism for 
berberine-induced apoptosis in SW620 human colonic carcinoma cells by targeting the 
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redos/ROS pathway and JNK/p38 pathway. Another study on the same cancer type 
showed that berberine could induce cell growth arrest and apoptosis of HCT-116 and 
SW480 cells by targeting two pro-apoptotic proteins ATF3 and NAG-1, in which the p53-
dependent pathway and the PKC, ERK, and GSK-3b pathways were involved, 
respectively (Rojsanga et al., 2007). Recent research further unraveled a vital role of p53 
related pathway in the berberine-mediated tumour suppression. Berberine could induce 
apoptosis of both A549 (p53+/+) and H1299 (p53-/-) human lung cancer cells, which 
effect was more pronounced in the A549 in both in vitro and in vivo studies (Katiyar et al., 
2009). Similarly, the cells with functional p53 were more susceptible to berberine than the 
p53-deficient cells, such as in SK-N-SH than SK-N-MC and in LNCaP than PC-3 cells 
(Choi et al., 2008 and 2009). 
(d) Berberine induces apoptosis via positive or negative regulation of various cytokines 
functioned in cellular network. These include up-regulation of GADD153 (Lin et al., 
2007b), inhibition of cyclooxygenase-2 (COX-2) and Mcl-1 (Kuo et al., 2005) and down-
regulation of nucleolar phosphoprotein nucleophosmin/B23 and telomerase (Wu et al., 
1999). A recent study demonstrated that nucleophosmin plays an important role in the 
regulation of apoptosis as one of Bax chaperons (Kerr et al., 2007). Also, this chaperon 
was found to be crucial and critical in regulation of the tumour suppressor p53 (Maiguel et 
al., 2004). GADD153, as a leucine zipper transcription factor, was found to mediate 
berberine-induced apoptosis in human cervical cancer Ca Ski cells, shown by elevated 
ratio of p53 and Bax/Bcl-2 proteins and increased levels of ROS and Ca
2+
 release from 
endoplasmic reticulum (ER). The proposed mechanism is that enforced expression of 
GADD153 sensitizes the cells to ER stress, which involves down-regulation of Bcl-2 and 
enhanced oxidant injury (McCullough et al., 2001).  
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In addition to direct apoptosis induction, a large number of studies demonstrated that 
berberine may exert indirect effects against cancers by involving the pro-inflammatory or NF-
κB pathway (Kuo et al., 2004; Lee et al., 2007b; Pandey et al., 2008), antioxidant defense 
system (Thirupurasundari, et al., 2009), anti-metastasis pathway (Lin et al., 2008; Kim et al., 
2008; Ho et al., 2009a) as well as synergistic effects with other chemotherapeutic agents (Liu 
et al., 2009b; Peng et al., 2008). The aforementioned berberine-induced ROS generation, may 
play a key role in modulating inflammatory responses through the inhibition of transcription 
factors such as NF-κB, which mediates expression of many pro-inflammatory mediators (Lin 
et al, 2006a; Jantova et al., 2007; Hsu et al., 2007). One recent study dissected the possible 
role of berberine in the NF-κB signaling pathway (Pandey et al., 2008). Some key components 
and downstream gene products in this pathway were mediated for berberine-induced apoptotic 
and anti-inflammatory activities. The mechanism in part, was ascribed to the direct 
modification of cysteine residue 179 in IKK, resulting in the stabilization of I-κB  and 
suppression of phosphorylation and nuclear translocation of p65, and finally inhibition of NF-
κB reporter activity. Moreover, NF-κB-regulated gene products were also suppressed by 
berberine including those functional in antiapoptosis (Bcl-XL, Survivin, IAP1, IAP2, and 
cFLIP), proliferation (cyclin D1), inflammation (COX-2), and invasion (MMP-9). These 
results established a strong link of enhanced apoptosis induced by TNF-  and 
chemotherapeutic agents and inhibition of TNF-induced cellular invasion with targeted NF-
κB signaling pathway by berberine.  
Berberine could inhibit motility and invasion ability of the highly metastatic lung cancer 
cell line, A549 cells, under non-cytotoxic concentrations via down-regulation of nuclear 
transcription factors e.g. c-fos, c-jun and NF-κB (Peng et al., 2006). Other explorations for the 
anti-metastasis function indicated that berberine could inhibit TNF- -induced MMP-9 
expression and cell invasion via mediating AP-1 DNA binding activity in MDA-MB-231 
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human breast cancer (Kim et al., 2008), induce down-regulation of MMP-1, -2, and -9 and 
related gene expressions in human SNU-5 gastric cancer cells (Lin et al., 2008), and down-
regulate u-PA, MMP-2 and -9 expressions through MAPK and NF-κB signaling pathways in 
human SCC-4 tongue squamous carcinoma cells (Ho et al., 2009). We found that anti-
invasion of berberine on HONE1 cell is a different mechanism which through inhibition of 
RhoA signaling pathway (Tsang et al., 2009). As regards the control of hematopoietic tumor 
cell, berberine could inhibit the migration of HL-60 cells, primary acute myeloid leukemia 
(AML) cells and leukemic stem cells (LSCs) induced by chemokine stromal cell-derived 
factor-1 (SDF-1), showing to be promising for prevention of leukemia (Li et al., 2008b). 
Berberine could also inhibit AP-1 (a complex of c-fos and c-jun) activation in human 
hepatoma cells (Fukuda et al., 1999b), oral cancer cells (Kuo et al., 2004) and breast cancer 
cells (Kim et al., 2008), as well as COX-2 expression in colon cancer cells (Fukuda et al., 
1999a).  
Several studies showed that berberine could confer synergistic effects against cancer in 
combination with ER antagonists, irradiation and other chemotherapeutic agents. A recent 
study by Liu et al. (2009b) demonstrated that the combined treatment of ER antagonists with 
berberine enhanced the growth inhibitory effect on MCF-7 cells (ER
+
) but not on MDA-MB-
231 cells (ER
-
). Peng et al. (2008) found that 5 and 10 M concentrations of berberine 
combined with irradiation significantly strengthened the radio-sensitivity on A549 cells, 
which molecular basis involved the induction of autophagic cell death as well as cell cycle 
G2/M arrest (only at 5 M berberine). Arsenic trioxide (As2O3) is usually indicated for the 
treatment of acute promyelocytic leukemia in vivo, and also induces apoptosis in various 
tumor cells in vitro. Lin et al. (2008) investigated the co-effects of berberine on As2O3-
mediated inhibition of cancer cell metastasis using rat and human glioma cell lines. As a result, 
berberine at 10 M enhanced the As2O3 (5 M) mediated reduction in motility and invasion of 
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glioma cells, which synergistic effects were achieved by the inhibition of PKC-  activity and 
downstream transcriptional factors, myc and jun, and MT1-MMP and MMP-2 in the PKC-
mediated signaling pathway involved in cancer cell migration. The synergistic anticancer 
effect using both As2O3 and berberine was also found in human neuroblastoma SH-SY5Y 
cells. The mechanism was based on the mitochondria/caspase-3 dependent signaling pathway 
(Kim et al., 2007). The synergy researches promote largely the development of multimodality 
or adjuvant chemotherapy in cancer treatment. However, the idea can be further derived from 
the principle of CM practice, in which different combination of the Chinese herbs could be 
used to treat the different syndromes under various diseases, and the research can be tuned 
fine by referring to the efficacious or proprietary Chinese formulae. A recent study (Wang et 
al., 2008) was based on such a formula, Zuo Jin Wan, which has a long-standing use for the 
treatment of gastrointestinal disorders especially inflammations. Berberine and evodiamine, 
another natural antitumour alkaloid, composing of the two major active ingredients of the 
formula, were combined to treat human hepatocellular carcinoma SMMC-7721 cells. The cell 
apoptosis, cell cycle distribution, and the level of TNF-  were remarkably elevated. 
It is worthwhile to note that berberine induced apoptosis in U937 cells without affecting the 
cell cycle or induction of necrosis in B16 or HeLa cells (Letašiová et al., 2006). Berberine 
could also antagonize the hypoxia-induced angiogenesis in gastric adenocarcinoma via HIF-
1α repression (Lin et al., 2004b). Therefore, the antineoplastic effects of berberine against 
various cancer cells may involve different mechanisms and is dependent on cell types and 
concentrations of the agents used.  
Based on the above studies and our ongoing research results on berberine, we can conclude 
that berberine has multiple antineoplastic effects mainly through cytotoxicity, anti-
proliferation, antiinvasion and antiinflammation mechanisms (Fig. 3). The main mechanism 
underlying induction of cytotoxicity, growth inhibition of berberine on cancer cells, could be 
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mediated through DNA topoisomerase I inhibition and cell cycle arrest which eventually 
induces apoptosis via the caspase-3 or Fas/FasL signal pathways. Berberine-induced 
anticancer effects were strongly correlated with its anti-inflammatory properties through 
cross-talk between different signaling pathways, such as NF-κB pathway for anti-
inflammatory effects and caspase-dependent pathways for apoptosis. The mechanisms 
underlying anti-invasion of berberine are relatively less understood at present. In addition to 
down-regulate u-PA, MMP-2 and -9 expressions, the signaling pathway involved in cell 
motility and invasion, such as the RhoA GTPase/ NF-κB pathway, may be considered (Fig. 3).  
 
3.3. Antiproliferation properties and underlying mechanisms of Huanglian  
 
Huanglian has also been used in many anticancer studies in such cancer types as human 
breast cancer (Li et al., 2000; Kang et al, 2005), human colon cancer (Li et al., 2000), human 
esophageal cancer (Iizuka et al., 2000a), human gastric cancer (Li et al., 2000), human 
leukemia (Lin et al., 2004a), human liver cancer (Lin et al., 2004a) and human pancreatic 
cancer (Hara et al., 2005). We have also reported that Huanglian had the strongest 
cytotoxicity among a selection of sixteen anticancer Chinese herbs in rat leukemia L-1210 
cells (Luo et al., 2002). A much higher inhibitory activity for growth of tumour cells was 
present in the water extract of Huanglian (or Huanglian extract, the most clinically applied 
form in CM), compared to extracts using other solvents for extraction. Cells treated for 3 
hours with 5 µg/ml of the Huanglian extract showed 89 % inhibition, while those treated with 
ethanol extract showed only 28 % inhibitory activity.  
In some studies, the antitumour effects of Huanglian extract were compared with berberine, 
in which either IC50 or ID50 values were used for assessment of in vitro cytotoxicity (Iizuka et 
al., 2000a and 2003; Lin et al., 2004a; Hara et al., 2005). Iizuka et al. (2000a) found that only 
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Huanglian had potent antitumour effects on various esophageal cancer cells among all 
ingredients of the complex prescription „Oren-to‟ (Huanglian Jiedu Decoction), which may be 
due to its major component, berberine. In another study by Lin et al. (2004a), purified 
berberine and coptisine (Fig. 1) were shown to be the active components, which were more 
potent than Huanglian extract against hepatoma and leukaemia cells. However, other studies 
(Kang et al, 2005; Hara et al., 2005; Iizuka et al., 2003; Li et al., 2000) on human pancreatic 
and gastric cancer cell lines demonstrated that Huanglian may not necessarily be less potent 
than berberine alone after normalization to levels of berberine present in the herb extract. The 
underlying mechanism may be related to genes or cellular pathways resistant to berberine‟s 
action that were overcome or regulated by other components in Huanglian (Fig. 1).  
On the other hand, Huanglian has also been found to mediate cancer cell apoptosis via  
similar pathways to berberine, including: a) the regulation of cytokines e.g. up-regulation of 
IFN-β and TNF-α (Kang et al, 2005); b) indirect effects against cancers involving the anti-
inflammatory pathways. Huanglian could inhibit IL-6 secretion in human esophageal tumour 
cells (Iizuka et al., 2000b); c) the anti-angiogenesis activity (Wang et al., 2004) and/or d) 
inhibition of DNA topoisomerase I (Kobayashi et al., 1995). These results have mirrored the 
diversity of Huanglian against various cancers. Even though the anti-inflammatory effects of 
Huanglian have demonstrated the art of CM for cancer therapies by removing heat and 
toxicity (inflammatory elements in cancerous pathogenesis) and promoting virtue (body 
immunity) simultaneously, there are still many uncertainties ahead about the underlying 
mechanisms need to be resolved in the future.  
 
3.4. Future approaches 
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Current studies broadly indicate the involvement of cell cytotoxicity, cell cycle regulatory 
machinery and apoptosis signaling pathways as targets of anticancer by berberine and 
Huanglian. The apoptotic cell death induced by berberine and Huanglian in cancer cells may 
be the result of cell cycle arrest. The detailed molecular mechanisms remain to be elucidated, 
especially for Huanglian, whose specialty for cancer prevention or therapy has been poorly 
studied. Similar to the antimicrobial action (Stermitz et al., 2000), synergism may play a key 
role in treatment of various tumours with Huanglian. The nature and identity of these 
synergistic components as well as the types for combination however, remain to be unveiled. 
Furthermore, detailed involvement of pro-apoptotic genes (e.g. p53, c-Myc and pRb), anti-
apoptotic genes (e.g. Bcl-2 gene family members or other cancer-specific genes), the types of 
cell death (apoptotic, autophagic and necrotic) and the downstream gene transcription 
(transcriptome analysis), translation (protein expression profile) and microRNAs (miRNA) in 
cells treated by berberine and Huanglian, remain to be fully clarified. The differential 
responses of cancer cells and their corresponding normal counterparts to berberine and 
Huanglian also need to be investigated, since only a few studies have been conducted to 
compare the cancer cell and non-neoplastic cell and show no insult on normal ones (Meeran et 
al., 2008; Mantena et al., 2006a; Hwang et al., 2006). It is encouraging to see that some 
transcriptional or regulatory factors, receptors as well as non-apoptosis cell death pathways 
are being identified as new targets of berberine and/or Huanglian such as the aforementioned 
pro-apoptotic proteins, nucleophosmin, HIF-1α, COX-2 and GADD153, RhoA/NF-κB 
signaling pathway and autophagic cell death, leading to a better understanding of the 
underlying mechanisms. 
 
4. Genomics and proteomics approaches to study antineoplastic effects of berberine and 
Huanglian 
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Very few genomics (or more exactly transcriptome analysis) and proteomics approaches 
have been carried out to investigate the inhibitory effects of Huanglian and berberine on 
tumour cells. With a microarray-based mRNA approach, Efferth et al (2005) had examined 
the expression values of 31 ABC transporter genes and another 9,706 genes from 60 NCI 
cancer cell lines treated with berberine. Twenty genes were identified that significantly 
predicted sensitivity or resistance of the cell lines to berberine and expression of 8 ABC 
transporters correlated well with the IC50 values for berberine. Among them, the ABCB1 
(MDR1) gene was validated to confer resistance to berberine in CEM/VCR1000 leukemia 
cells. Another study (Hara et al, 2005) used 8 human pancreatic cancer cell lines which 
examined the ID50 of Huanglian. By hierarchical cluster analysis, the investigators identified 
27 Huanglian-related genes using DNA microarray data from 12,600 genes and suggested that 
berberine can account for the majority of the anti-proliferation activity of Huanglian. 
Previously, gene expression patterns explored by the same group using pancreatic cancer cells 
and oligonucleotide microarrays, also led to the identity of 12 genes from approximately 11, 
000 genes showing a strong correlation (r
2
>0.81) with the ID50 values of both agents, 
suggesting that these genes are associated with the anti-proliferative activity of berberine in 
Huanglian (Iizuka et al., 2003). These genomic approaches help to identify novel marker 
genes and cell signaling pathways affected by berberine and Huanglian. 
Similar to mRNA expression based on transcriptome analysis, proteomics also provides 
high-throughput analysis of expressed proteins in berberine treated cells in examining or 
predicting cell response to many external stimulus. However, this may not correlate with 
changes in mRNA levels due to complicated protein-protein or protein-DNA interactions (Fell, 
2001). A study conducted by Tan et al. (2006) investigated differential protein expression in a 
human liver cancer cell line, HepG2, after berberine treatment. The results showed a network 
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of proteins involved in the MAPK phosphor-relay systems, metabolism, and regulation of cell 
cycle and DNA damage responses. This work serves as a paradigm for further studies on the 
molecular mechanisms of berberine or Huanglian against many tumours. 
 
5. Computer–aided molecular design and prediction of cell response to berberine and 
analogs 
 
Several studies have reported the structure and activity of berberine as a small molecule 
ligand. In one study, the X-ray crystal structures of the human topoisomerase I-DNA 
cleavable complex, combined with a Sybyl software package, have been used to analyse the 
properties of berberine as a potent topoisomerase I poison for a next generation anticancer 
drug (Kettmann et al, 2004a). Another study using NCI database by COMPARE analysis, 
investigated the responses of 60 cancer cell lines to berberine (the IC50 values) and examined 
the correlation to another 43,177 compounds included in the database, in order to establish the 
molecular determinants of response of tumour cells to berberine. Preliminary research results 
were able to correlate the sensitivity or resistance of the cell lines with berberine, based on 
microarray-mRNA expression assays (Efferth et al, 2005). Recent progress in structural and 
functional aspects of telomeric G-quadruplex and telomerase, demonstrated that the preferable 
chemicals to telomerase activity (another promising near-universal anticancer target) could be 
designed with high selection, specificity and fewer side effects. One such research, targeting 
telomerase, found that the 9-substituted derivatives of berberine displayed a stronger binding 
affinity with the telomeric G-quadruplex and corresponding high inhibitory effect against 
telomerase activity (Zhang et al., 2007). These molecular modeling studies, have enabled 
exploration of the actions of small anticancer drugs such as berberine in a more precise and 
selective fashion. 
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6. In vivo studies in animals and humans 
 
6.1. Huanglian 
 
As aforementioned, Huanglian can remove damp-induced heat and counteract toxicity, both 
of which are related to tumour pathogenesis in CM (Chinese Herbals Editor Board, 1999; Liao 
et al, 2003).  Huanglian is now recorded in some anticancer Chinese herbal books (Bo et al, 
2002; Xu et al, 1997; Tse, 1977) and can be used in daily CM clinical practice for cancer 
treatment. Huanglian and Huanglian formulae (with Huanglian as the main herb) such as 
Huanglian Jiedu decoction have been described as anticancer agents and used for treating 
pancreas cancer, breast cancer, liver cancer and colon cancer in clinical Chinese herbal books 
(Qian, 1980; Chang, 1998). Owing to the potential in vitro results in the treatment of cancers, 
a phase I dose escalation study of Huanglian in patients with advanced solid tumours is 
currently ongoing at Memorial Sloan-Kettering Cancer Center (ClinicalTrials.gov, 2009). 
An in vivo study showed that Huanglian Jiedu decoction can significantly inhibit the H22 
tumour in mice in a dose-dependent manner, all of the Huanglian Jiedu decoction in different 
dosage groups could highly inhibit the proliferation of 4 human cancer cell lines: Swille, SPC-
A-1, SGC-7901 and MCF-7 (Sun et al., 2006).   
 
6.2. Berberine 
 
The effect of berberine on WEHI-3 leukemia cells in vivo was examined. The results 
showed that Mac-3 and CD11b markers, which indicate inhibition of differentiation of 
macrophages and granulocytes precursors, were down-regulated after treatment. There was no 
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affect on the expression of CD14 marker, except for the CD19 marker, which indicated 
promotion of differentiation of the B-cell precursors. The spleen sizes from mice treated with 
berberine, were found to be lower when compared to those from untreated animals (Yu et al., 
2007). The treatment with berberine was also found to be able to inhibit the leukemia growth 
induced by Friend murine leukemia virus in BALB/c mice and further support its potential for 
virally induced cancer chemoprevention (Harikumar et al., 2008). On the other hand, in vivo 
studies involving solid tumours were usually conducted with the murine xenograft animal 
models. The anticancer activity of berberine was examined in a transplantable B16 tumour 
system at a range of doses from 1 mg/kg to 10 mg/kg. Significant reduction of tumour volume 
was observed on day 16 at doses of 5 and 10 mg/kg. The dose of 1 mg/kg stimulated increase 
of tumour mass, but other tested concentrations, 5 and 10 mg/kg, reduced the tumour mass 
(Letašiová et al., 2005a). In other studies, the treatment with berberine (10mg/kg of body 
weight) inhibited significantly the human tongue cancer growth in xenograft mice, showing 
the promise for tongue cancer prevention in clinic (Ho et al., 2009b). The oral administration 
of berberine inhibited the growth of A549 (p53+/+) and H1299 (p53-/-) lung tumours 
inoculated subcutaneously in athymic nude mice, especially more effective in A549 tumour 
xenograft mice (58% tumour volume reduction vs. 35% in H1299 at a dose of 100 mg/kg) 
(Katiyar et al., 2009). Berberine also strongly suppressed the growth of human prostate cancer 
xenograft in mice, in which LNCaP xenografts with p53 expression were more easily affected 
by apoptotic cell death than those inoculated with p53-deficient PC-3 cells (Choi et al., 2009).  
Furthermore, the chemomodulatory activity of Alstonia scholaris extract (ASE) was 
investigated in combination with berberine hydrochloride (BCL) on Ehrlich ascites 
carcinoma-bearing mice (Jagetia and Baliga, 2004). The tumour-bearing animals were 
injected with various doses of ASE, and 8 mg/kg of BCL (one-fifth of the LD50) was 
combined with different doses of ASE (60-240 mg/kg). The combination of 180 mg/kg of 
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ASE with 8 mg/kg of BCL showed the greatest antitumour effect; the number of tumour-free 
survivors in the treated group was greater, median and average survival time increased to 47 
and 40.5 days, respectively, compared to the non-treated group. Similarly, 180 mg/kg of ASE 
in combination with different doses of BCL (2-12 mg/kg), showed a dose-dependent increase 
in anticancer activity up to 8 mg/kg of BCL. The best effect was observed when 180 mg/kg of 
ASE was combined with 6 or 8 mg/kg of BCL, where an increase in antineoplastic activity 
was observed. Clinically, ionizing radiation is one of most commonly used strategies for lung 
cancer therapies, however, how to maintain the radio-sensitizing effects still remains a 
challenge. In the study by Peng et al. (2008), berberine being given intraperitoneally at 2.0 
mg/kg twice weekly in combination with irradiation almost abridged the growth of implanted 
Lewis lung carcinoma in C57BL/6 mice. The mechanism was in a good agreement with the 
autophagy-mediated tumor diminishment. The results verified the synergistic cytotoxic effect 
of berberine and irradiation. 
Berberine was also found to significantly inhibit carcinogenesis induced by 20-
methylcholanthrene (200 g/0.1 mL/mouse) or N-nitrosodiethylamine (NDEA; 0.02% NDEA 
in distilled water, 2.5 mL/animal by gavage, five days a week for 20 weeks) in a dose-
dependent manner using mice and rats. Administration of berberine (0.5, 2.5 or 5.0 mg/kg) 
could significantly reduce the incidence of tumour in animals after injection of 20-
methylcholanthrene, with increased life spans observed compared with controls. When 
berberine (10, 25 or 50 mg/kg) was administered simultaneously with NDEA, the markers of 
liver injury (liver weight, gamma-glutamyl transpeptidase activity and glutathione S-
transferase level) were reduced significantly compared with animals treated with NDEA alone. 
Similar decreases in the serum levels of lipid peroxide, bilirubin and glutamate pyruvate 
transaminase were also noted. Morphology of liver tissue and levels of marker enzymes 
indicated that berberine offered protection against chemical carcinogenesis (Anis et al., 2001).  
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6.3. Uncertainties 
 
Although Huanglian has been used clinically for treating cancers in China, a gateway to 
comprehensive clinical trial is just on the very preliminary stage (ClinicalTrials.gov, 2009). 
On the other hand, a note of caution was observed in a study using berberine and Huanglian 
to treat hepatoma cancer cells in which high cytotoxic effect in peripheral blood mononuclear 
cells was observed (Lin et al., 2004a).  In addition, antagonistic actions of berberine on other 
chemotherapeutic agents e.g. paclitaxel-induced cytotoxicity in oral (OC2), gastric (SC-M1) 
and colon (COLO 205) cancer cells was also observed through up-regulation of MDR1 (Lin et 
al., 1999), which may compromise the actions of other chemotherapeutic agents. These issues 
should be validated in in vivo studies comparing with berberine, Huanglian and other 
chemotherapeutic agents.  
 
7. Adverse effects under Huanglian and berberine treatments 
 
7.1. Huanglian 
 
According to unpublished data, Huanglian has no major side effects after being p.o. 
administrated 200 mg/kg daily for three weeks. The acute toxicity study showed that LD50 of 
Huanglian was 4.89 g /kg in mice by gavage (Qiu et al., 2004a); and at a daily dose of 3 g/kg 
for 8 days Huanglian could markedly elevate AST level in serum (Qiu et al., 2004b). There 
were some reports suggesting that Huanglian may cause haemolytic jaundice and nuclear 
jaundice of the newborn infants with glucose-6-phosphate dehydrogenase deficiency (Yang 
and Gao, 1996).  However, neither experimental studies nor clinical investigations found any 
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related evidence on the offsprings after administration directly or through pregnant mothers 
with Huanglian or Huanglian formulae. In contrary, Huanglian is commonly used as a single 
drug or Huanglian formulae in CM to prevent infections in newborn infants. Prescriptions of 
Huanglian are not prohibited in Chinese medicines for pregnant women (Gao et al, 2002).  
 
7.2. Berberine 
 
Berberine sulfate also has not caused any histopathological changes in rat tissues and 
organs when administered for 6 weeks in 500 mg/kg daily oral doses (Kowalewski et al., 
1975). The LD50 values for berberine have showed great variation among different species, or 
may be dependent on administrative routes. The i.v. administration of berberine and its 
analogs may induce higher toxic effects than p.o.. In an earlier study, MLD of BCL in s.c. 
administration to mice was found to be 10 mg/kg, while BCL was not toxic by oral 
administration in mice (Aoyama, 1951). In another study, the LD50 of berberine sulfate was 
24.3 mg/kg in mice under i.p. administration but 392 mg/kg on oral route (Sabir and Bhide, 
1971). In rats, LD50 of berberine sulfate has been reported more than 1g/kg on p.o., 88.5 
mg/kg on i.p., and 14.5 mg/kg on i.m. administration (Kowalewski et al., 1975). On the other 
hand, LD50 for i.p. administration to mice and rats were found to be 30 mg/kg and 205 mg/kg 
respectively, allowing mice to be approximately six-fold more sensitive to toxicity from 
berberine (Registry of the Toxic Effects of Chemical Substances, 1998). Berberine chloride 
dihydrate (BCD) was evaluated for developmental toxicity in rats and mice (Jahnke, et al., 
2006). In this study, there were no maternal deaths, however adverse effects were noted in 
maternal rat, but not in fetus. The lowest observed adverse effect level (LOAEL) in maternal 
rat remained at 531 mg/kg/day based on the feeding study and developmental toxicity.  The 
no observed adverse effect level (NOAEL) was raised to 1000 mg/kg/day BCD based on the 
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gavage study. In mice, 33% of the treated females died. Surviving animals had increased 
water intake, and average fetal body weight per litter decreased 5-6%, with no change in live 
litter size. Maternal toxicity LOAEL remained at 841 mg/kg/day BCD, based on increased 
water consumption, while developmental toxicity LOAEL was raised to 1000 mg/kg/day 
BCD based on decreased fetal body weight. Developmental toxicity NOAELs in both rat and 
mice studies are about 500 times higher than the amount of berberine taken for dietary 
supplements (e.g., goldenseal) by humans and about 60-100 times higher than a 
pharmacologic dose.  
The most common adverse responses of berberine include constipation, laxative, 
anaphylaxis and other skin allergies such as dermatitis and rashes, and overdose may cause 
respiratory and circulatory system problems. Furthermore, berberine could displace bilirubin 
from serum-binding proteins, causing jaundice, kernicterus, and brain damage in infants 
(Bateman et al., 1998; Chan, 1993, 1994). Therefore, exposure of pregnant women to 
berberine is not recommended because it may lead to jaundice and kernicterus in the fetus 
(Chan, 1993).  
 
8. Concluding remarks 
 
Huanglian is a Chinese medicinal herb and berberine constitutes its major active 
component. It has been used clinically in certain CM formulae for treating inflammatory 
diseases and cancers. There are three distinct medicinal agents related to Huanglian which are 
used in CM, that is, Chinese composite formulae containing Huanglian (e.g., Huanglian Jiedu 
decoction), the single herb Huanglian, and single compound berberine, however, their 
physiochemical nature, pharmacological profiles and clinical indications in CM are somewhat 
similar to each other. Huanglian is the main active herb of Huanglian Jiedu decoction, both of 
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which contain the main active principal, berberine. Hence, in the standpoint of chemistry, in 
that berberine is the major active compound against cancer, all three agents are strongly 
correlated. Actually, their clinical uses in modern CM practice have largely been benefited 
from basic research achievements on berberine. In return, the clinical successes further 
promote research activities and the understanding of molecular mechanisms as addressed 
above. In this review, recent progresses in research of berberine and Huanglian against 
cancers are highlighted.  
In CM, there were no direct claims of Huanglian to cancer therapies in early history. 
However, there are many indications of anti-tumour effects in Chinese herbs with similar core 
properties to Huanglian such as clearing damp-heat, fire and toxicity (they can be conceived 
as characteristics of inflammatory diseases nowadays) and their perspective uses in treatment 
of diseases with tumour symptoms, which can be derived from both traditional knowledge and 
modern basic research. The early development of berberine and Huanglian as botanic drugs to 
treat infections and inflammations may also be helpful to understand more clearly their 
potential value as anticancer agents. The positive results of carcinostatic research of 
berberine-containing plants in early 1900s and the purification of berberine have encouraged 
researchers to explore antineoplastic properties of Huanglian and berberine in conventional 
approaches. Even though many other pharmacological effects have been reported in berberine 
and Huanglian including lowering of blood cholesterol and blood pressure and decrease of 
blood glucose, the potential use of berberine and Huanglian as antineoplastic agents has 
triggered new excitement and enthusiasm in investigations. The relatively low toxicities at 
therapeutic level for both Huanglian and berberine also show additional benefit for their 
further development. 
   Berberine is an essential anticancer compound in Huanglian. However, it is interesting to 
note in some studies that Huanglian extract may be more effective than berberine alone (Hara 
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et al., 2005; Iizuka et al., 2003; Li et al., 2000). One explanation is that other components in 
Huanglian may act synergistically with berberine (Fig. 1). The identities of these components 
and their mode of action are still unknown. This would suggest that berberine alone might not 
fully represent the therapeutic properties of Huanglian used in CM practice. This point is also 
best illustrated by the use of Huanglian formulae (with the main herb as Huanglian) in CM, in 
which various ingredients follow the rule of drug synergism and compatibility (Qiu, 2007). 
The synergy research in combination with berberine and other typical tumour-killing 
approaches have drawn a large attention so far, however, it may be greatly promoted with the 
full understanding of the intrinsic principle implied in CM. 
The anticancer effects of berberine and Huanglian mainly involve cytotoxicity, anti-
proliferation and anti-invasion. It is clear that berberine is able to inhibit the growth of various 
types of cancer cells by inhibiting DNA topoisomerase I, inducing cell cycle arrest and 
apoptosis mainly through caspase-3 or Fas/FasL signaling pathways. Current studies also 
demonstrate that berberine-induced anticancer effects are strongly correlated with anti-
inflammatory properties through cross-talk between different signaling pathways targeted, 
such as NF-κB pathway for anti-inflammatory effects and caspase-dependent pathways for 
apoptosis. This evidence may further establish a link with the art of CM to treat cancers from 
its original standpoint by removing heat and toxicity (inflammatory elements in cancerous  
pathogenesis). In addition to down-regulation of u-PA and matrix metalloproteinases (MMPs) 
expression, the mechanism underlying anti-angiogenic, anti-invasive and anti-metastatic 
effects of berberine is less understood at present, which warrant further investigation. We 
propose that inhibition of the RhoA GTPase/NF-κB pathway may be involved anti-invasive 
effect of berberine according to our current study. In vivo studies in animals will also be 
needed to validate the in vitro studies.    
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All in all, most studies and discoveries on the anticancer properties of berberine and 
Huanglian have just been conducted and found during the last ten years, many more details 
for their clinical potential, such as cancer types, molecular targets, dosages, and indication on 
different individuals, remain uncovered. Therefore, further studies are still warranted in order 
to transfer the knowledge for antineoplastic actions of berberine and Huanglian to clinical 
applications by using advanced approaches.  
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Figure captions 
 
Fig. 1 The structures of berberine and other key protoberberine-type alkaloids contained in 
Huanglian 
 
Fig. 2 The natural habitat and cultivation of Huanglian (Coptis chinensis Franch.) in two 
famous endemic regions in China. Upper panel (pictures kindly provided by government of 
Shizu county of Chongqing city): A. An exhibition board showed the GAP authorized field for 
Huanglian cultivation in Shizu county of Chongqing city, and this board indicated the area has 
been certificated by the SFDA (state food and drug administration) of China for the 
cultivation and production of the official Huanglian, whose quality and safety can be 
guaranteed. The area with a exhibition board also plays an important role in the promotion, 
guidance, and paradigm of the herb cultivation in other appropriate areas; B. one GAP base 
for Huanglian cultivation, which demonstrated that ecological conditions should be humid, 
cool, shadowed, at high altitude around 1500-2300 m sea level and with high organic and 
weak acidic soil; C. A photo of one single plant of Huanglian taken in April. Lower panel 
(photo taken by ourselves): a. An exhibition board showed the GAP authorized field for 
Huanglian cultivation in Lichuan county of Hubei Province; b. A GAP base for Huanglian 
cultivation, with the same conditions as B; c. A photo of one single plant of Huanglian taken 
in April.  
 
Fig. 3 A schematic diagram of molecular machinery for antineoplastic properties of berberine. 
Berberine has multiple anticancer effects through direct cell toxicity, anti-proliferation and 
anti-invasion pathways. Bold arrows with number 1, 2, 3, 4, 5 and 6 show the different cell 
signaling pathways targeted by berberine.: stimulation or positive regulation;  : not yet 
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completely demonstrated action; : inhibition. 1. Cdki–Cdk-cyclin cascade; 2. 
Mitochondrial/caspase-dependent pathway; 3. Fas/FasL signaling pathway; 4. DNA damage 
via topoisomerase I inhibition, and followed by p53 pathway in response; 5. NF-κB pathway; 
6. RhoA GTPase/NF-κB pathway 
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